Functional role of residue 193 (chymotrypsin numbering) in serine proteases: Influence of side chain length and β-branching on the catalytic activity of blood coagulation factor XIa

Biochemistry

Volumn 47, Issue 5, 2008, Pages 1326-1335

  Schmidt, Amy E ^a   Sun, Mao Fu ^b   Ogawa, Taketoshi ^b   Bajaj, S Paul ^a,c   Gailani, David ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c JOINT REPLACEMENT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; BLOOD; CATALYSIS; CATALYST ACTIVITY; ENZYME ACTIVITY; MOLECULAR MODELING;

BLOOD COAGULATION PROTEASES; STERIC CONFLICTS;

ENZYME INHIBITION;

4 AMINOBENZAMIDINE; ALANINE; AMYLOID PRECURSOR PROTEIN; ANTITHROMBIN; ASPARTIC ACID; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 9; CHYMOTRYPSIN; DYFLOS; GLUTAMINE; GLYCINE; ISOLEUCINE; SERINE PROTEINASE; VALINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; BLOOD CLOTTING; CATALYSIS; ENZYME ACTIVITY; HYDROLYSIS; MACROMOLECULE; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE; STEREOCHEMISTRY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID BETA-PROTEIN PRECURSOR; ANTITHROMBINS; BENZAMIDINES; CARBAMATES; FACTOR IX; FACTOR XIA; HUMANS; ISOFLUROPHATE; KINETICS; MODELS, MOLECULAR;

EID: 38849105588     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi701594j     Document Type: Article

References (57)

1. Neaurath, H., and Walsh, K. A. (1976) Role of proteolytic enzymes in biological regulation (a review), Proc. Natl. Acad. Sci. U.S.A. 73, 3825-3832.
2. Davie, E. W., Fujikawa, K., and Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation, Biochemistry 30, 10363-10370.
3. Sim, R. B., and Tsiftsoglou, S. A. (2004) Proteases of the complement system, Biochem. Soc. Trans. 32, 21-27.
4. Busuttil, S. J., Ploplis, V. A., Castellino, F. J., Tang, L., Eaton, J. W., and Plow, E. F. (2004) A central role for plasminogen in the inflammatory response to biomaterials, J. Thromb. Haemostasis 10, 1798-1805.
5. Daci, E., Everts, V., Torrekens, S., Van 1176.Herck, E., Tigchelaar-Gutterr, W., Bouillon, R., and Carmeliet, G. (2003) Increased bone formation in mice lacking plasminogen activators, J. Bone Miner. Res. 18, 1167-1176.
6. Bayer, C. A., Halsell, S. R., Fristrom, J. W., Kiehart, D. P., and von Kalm, L. (2003) Genetic interactions between the RhoA and Stubble-stubbloid loci suggest a role for a type II transmembrane serine protease in intracellular signaling during Drosophila imaginal disc morphogenesis, Genetics 165, 1417-1432.
7. Honda, A., Siruntawineti. J., and Baba, T. (2002) Role of acrosomal matrix proteases in sperm-zona pellucida interactions, Hum. Reprod. Update 5, 405-412.
8. Blow, D. (1990) Enzymology. More of the catalytic triad, Nature 343, 694-695.
9. Perona, J. J., and Craik, C. S. (1995) Structural basis of substrate specificity in the serine proteases, Protein Sci. 4, 337-360.
10. Schechter, I., and Berger, A. (1967) On the size of the active site in proteases. I. Papain, Biochem. Biophys. Res. Commun. 27, 157-162.
11. Timm, D. E. (1997) The crystal structure of the mouse glandular kallikrein-13 (prorenin converting enzyme), Protein Sci. 6, 1418-1425.
12. Parry. M., Jacob, U., Huber, R., Wisner, A., Bon, C., and Bode, W. (1998) The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases, Structure 6, 1195-1206.
13. Katona, G., Berglund, G., Hajdu, J., Graf, L., and Szilagyi, L. (2002) Crystal structure reveals basis for the inhibitor resistance of human brain trypsin, J. Mol. Biol. 315, 1209-1218.
14. van Holde, K. E., Johnson, W. C., and Ho, P. S. (1998) Principles of Physical Biochemistry, pp 42-44, Prentice Hall, Upper Saddle River, NJ.
15. Zivelin, A., Ogawa, T., Bulvik, S., Landau, M., Toomey, J., Lane, J., Seligsohn, U., and Gailani, D. (2004) Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation, J. Thromb. Haemostasis 2, 1782-1789.
16. Thompson, A. R., Schoof, J. M., Weinmann, A. F., and Chen, S.-H. (1992) Factor IX mutations: rapid, direct screening methods for 20 new families with hemophilia B, Thromb. Res. 65, 289-295.
17. Giannelli, F., Green, P. M., Sommer, S. S., Lillicrap, D. P., Ludwig, M., Schwaab, R., Reitsma, P. H., Goossens, M., Yoshioka, A., and Brownlee, G. G. (1994) Haemophilia B: database of point mutations and short additions and deletions, Nucleic Acids Res. 22, 3534-3546.
18. Saad, S., Rowley, G., Tagliavacca, L., Green, P. M., and Giannelli, F. (1994) First report on UK database of haemophilia B mutations and pedigrees. UK Haemophilia Centres, Thromb. Haemostasis 71, 563-570.
19. Van de Water, N. S., Williams, R., Berry, E. W., Ockelford, P. A., and Browett, P. J. (1996) Factor IX gene mutations in haemophilia B: A New Zealand population based study, Haemophilia 2, 24-27.
20. Bajaj, S. P., Spitzer, S. G., Welsh, W. J., Warn-Cramer, B. J., Kasper, C. K., and Birktoft, J. J. (1990) Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme, J. Biol. Chem. 265, 2956-2961.
21. Bernardi, F., Liney, D. L., Patracchini, P., Gemmati, D., Legnani, C., Arcieri, P., Pinotti, M., Redaelli, R., Ballerini, G., Pemberton, S., Wacey, A. I., Mariani, G., Tuddenham, E. G. D., and Marchetti, G. (1994) Molecular defects in CRM+ factor VII deficiencies: modeling of missense mutations in the catalytic domain of FVII, Br. J. Haematol. 86, 610-618.
22. Bernardi, F., Castaman, G., Pinotti, M., Ferraresi, P., Di Iasio, M. G., Lunghi, B., Rodeghiero, and Marchetti, G. F. (1996) Mutation pattern in clinically asymptomatic coagulation factor VII deficiency, Hum. Mutat. 8, 108-115.
23. Bouma, B. N., and Griffin, J. H. (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII, J. Biol. Chem. 252, 6432-6437.
24. Butenas, S., and Mann, K. G. (2002) Blood coagulation, Biochemistry (Moscow) 67, 3-12.
25. Fujikawa, K., Chung, D. W., Hendrickson, L. E., and Davie, E. W. (1986) Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein, Biochemistry 25, 2417-2424.
26. Sun, M. F., Zhao, M., and Gailani, D. (1999) Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX, J. Biol. Chem. 274, 36373-36378.
27. Lottenberg, R., and Jackson, C. M. (1983) Solution composition dependent variation in extinction coefficients for p-nitroaniline, Biochem. Biophys. Acta 742, 558-564.
28. Halfman, C. J. (1981) Concentrations of binding protein and labeled analyte that are appropriate for measuring at any analyte concentration range in radioimmunoassays, Methods Enzymol. 74, 481-497.
29. Cheng, Y.-C., and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099-3108.
30. Craig. D. A. (1993) The Cheng-Prusoff relationship: something lost in the translation, Trends Pharmacol. Sci. 14, 89-91.
31. Camire, R. M. (2002) Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site, J. Biol. Chem. 277, 37863-37870.
32. Bajaj, S. P., and Birktoft, J. J. (1993) Human factor IX and factor IXa, Methods Enzymol. 222, 96-128.
33. Beith, J. G. (1984) In vivo significance of kinetic constants of protein proteinase inhibitors, Biochem. Med. 32, 287-397.
34. Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors, Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301.
35. Papagrigoriou, E., McEwan, P. A., Walsh, P. N., and Emsley, J. (2006) Crystal structure of the factor XI zymogen reveals a pathway for transactivation, Nat. Struct. Mol. Biol. 13, 557-558.
36. Jin, L., Pandey, P., Babine, R. E., Weaver, D. T., Abdel-Meguid, S. S., and Strickler, J. E. (2005) Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors, Acta Crystallogr., Sect. D: Biol. Crystallogr. 61, 1418-1425.
37. Jin, L., Pandey, P., Babine, R. E., Gorga, J. C., Seidl, K. J., Gelfand, E., Weaver, D. T., Abdel-Meguid, S. S., and Strickler, J. E. (2005) Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions, J. Biol. Chem. 280, 4704-4712.
38. Navaneetham, D., Jin, L., Pandey, P., Strickler, J. E., Babine, R. E., Abdel-Meguid, S. S., and Walsh, P. N. (2005) Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2, J. Biol. Chem. 280, 36165-36175.
39. Li, W., Johnson, D. J., Esmon, C. T., and Huntington, J. A. (2004) Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin, Nat. Struct. Mol. Biol. 11, 857-862.
40. Huber, R., and Bode, W. (1978) Structural basis of the activation and action of trypsin, Acc. Chem. Res. 11, 114-122.
41. Kraut, J. (1977) Serine proteases: Structure and mechanism of catalysis. Ann. Rev. Biochem. 46, 331-358.
42. Schmidt, A. E., Stewart, J. E., Mathur, A., Krishnaswamy, S., and Bajaj, S. P. (2005) Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding, J. Mol. Biol. 350, 78-91.
43. DiScipio, R., Kurachi, K., and Davie, E. (1978) Activation of human factor IX (Christmas Factor), J. Clin. Invest. 61, 1528-1538.
44. Ogawa, T., Verhamme, I. M., Sun, M. F., Bock, P. E., and Gailani, D. (2005) Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX, J. Biol. Chem. 280, 23523-23530.
45. Aktimur, A., Gabriel, M. A., Gailani, D., and Toomey, J. R. (2003) The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa, J. Biol. Chem. 278, 7981-7987.
46. Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1991) Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa, J. Biol. Chem. 266, 24190-24197.
47. Soons, H., Janssen-Claesson, T., Tans, G., and Hemker, H. (1989) Inhibition of factor XIa by antithrombin III, Biochemistry 26, 4624-4629.
48. Beeler, D., Marcum, J., Schiffman, S., and Rosenberg, R. (1986) Interaction of factor XIa and antithrombin in the presence and absence of heparin, Blood 67, 1488-1492.
49. Schmaier, A. H., Dahl, L. D., Rozemuller, A. J., Roos, R. A., Wagner, S. L., Chung, R., and Van Nostrand, W. E. (1993) Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa, J. Clin. Invest. 92, 2540-2545.
50. Schmidt, A., Ogawa, T., Gailani, D., and Bajaj, S. P. (2004) Structural role of Gly(193) in serine proteases: investigations of a G555E (Gly193 in chymotrypsin) mutant of blood coagulation factor XI, J. Biol. Chem. 279, 29485-29492.
51. Toth, J., Gombos, L., Simon, Z., Medveczky, P., Szilagyi, L., Graf, L., and Malnasi-Csizmadia, A. (2006) Thermodynamic analysis reveals structural rearrangement during the acylation step in human trypsin 4 on 4-methylumbelliferyl 4-guanidinobenzoate substrate analogue, J. Biol. Chem. 281, 12596-12602.
52. Bobofchak, K. M., Pineda, A. O., Mathews, F. S., and Di Cera, E. (2005) Energetic and structural consequences of perturbing Gly193 in the oxyanion hole of serine proteases, J. Biol. Chem. 280, 25644-25650.
53. Bajaj, S. P., Schmidt, A. E., Agah, S., Bajaj, M. S., and Padmanabhan, K. (2006) High resolution structures of p-aminobenzamidine- and benzamidine-VIIa/soluble tissue factor: unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+, and Zn2+ sites in factor VIIa, J. Biol. Chem. 281, 24873-24888.
54. Hopfner, K. P., Lang, A., Karcher, A., Sichler, K., Kopetzki, E., Brandstetter, H., Huber, R., Bode, W., and Engh, R. A. (1999) Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding, Structure 7, 989-996.
55. Katona, G., Berglund, G. I., Hajdu, J., Graf, L., and Szilagyi, L. (2002) Crystal structure reveals basis for the inhibitor resistance of human brain trypsin, J. Mol. Biol. 315, 1209-1218.
56. Parry, M. A. A., Jacob, U., Huber, R., Wisner, A., Bon, C., and Bode, W. (1998) The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases, Structure 6, 1195-1206.
57. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models, Acta Crystallogr. A 47, 110-119.